Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06739330

Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease

This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Thyroid Dysfunction Metabolic Dysfunction-Associated Fatty Liver Disease

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

One of the most common causes of chronic liver diseases worldwide is metabolic dysfunction-associated fatty liver disease (MAFLD), which affects about 30% of adults. Thyroid hormones are critical in maintaining metabolic homeostasis throughout life and are intimately linked to the liver.

Dysfunctions of the thyroid gland have been implicated as one of the most important risk factors of MAFLD due to its important role in the hepatic synthesis of fatty acid and cholesterol. Maintaining liver metabolism requires thyroid function to be normal, while thyroid disorders may lead to liver disease progression.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Both sexes.
  • Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).

Exclusion criteria

  • History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
  • Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
  • Viral hepatitis.
  • Pregnant women.

Treatment and study plan

FibroScan

Device

Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.

Primary outcomes

  1. Level of free triiodothyronine (FT3)

    Time frame: After the sample is taken (up to 5 minutes)

    Free triiodothyronine (FT3) will be measured using chemiluminescent immunoassay analysis.

Secondary outcomes

  1. Level of free thyroxine (FT4)

    Time frame: After the sample is taken (up to 5 minutes)

    Free thyroxine (FT4) will be measured using chemiluminescent immunoassay analysis.

  2. Level of thyroid stimulating hormone

    Time frame: After the sample is taken (up to 5 minutes)

    Thyroid stimulating hormone will be measured using chemiluminescent immunoassay analysis.

  3. Relation between gender and thyroid function

    Time frame: After the sample is taken (up to 5 minutes)

    Relation between gender and thyroid function will be assessed.

  4. Correlation between metabolic data and thyroid function tests

    Time frame: After the sample is taken (up to 5 minutes)

    Correlation between metabolic data and thyroid function tests will be assessed.

Study contacts

Contact information is provided by the study sponsor or research team.

Shimaa A Meshaal, MD

CONTACT

[email protected]

00966559806580

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 18, 2024
Registry last updated
Dec 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.